Zannettino AC - Search Results

1

SAMSN1 is a tumor suppressor gene in multiple myeloma.

Noll JE, Hewett DR, Williams SA, Vandyke K, Kok C, To LB, Zannettino AC. Noll JE, et al. Among authors: zannettino ac. Neoplasia. 2014 Jul;16(7):572-85. doi: 10.1016/j.neo.2014.07.002. Neoplasia. 2014. PMID: 25117979 Free PMC article.

2

Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.

Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, Findlay DM, Bardy P, Zannettino AC. Farrugia AN, et al. Among authors: zannettino ac. Cancer Res. 2003 Sep 1;63(17):5438-45. Cancer Res. 2003. PMID: 14500379

3

The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro.

Pan B, To LB, Farrugia AN, Findlay DM, Green J, Gronthos S, Evdokiou A, Lynch K, Atkins GJ, Zannettino AC. Pan B, et al. Among authors: zannettino ac. Bone. 2004 Jan;34(1):112-23. doi: 10.1016/j.bone.2003.08.013. Bone. 2004. PMID: 14751568

4

The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).

Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC. Pan B, et al. Among authors: zannettino ac. J Bone Miner Res. 2004 Jan;19(1):147-54. doi: 10.1359/jbmr.2004.19.1.147. J Bone Miner Res. 2004. PMID: 14753746 Free article.

5

Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.

Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N, Gronthos S. Zannettino AC, et al. Cancer Res. 2005 Mar 1;65(5):1700-9. doi: 10.1158/0008-5472.CAN-04-1687. Cancer Res. 2005. PMID: 15753365

6

Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor.

Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR. Zannettino AC, et al. J Cell Physiol. 2005 Aug;204(2):714-23. doi: 10.1002/jcp.20354. J Cell Physiol. 2005. PMID: 15799029

7

An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.

Zannettino AC, Farrugia AN, To LB, Atkins GJ. Zannettino AC, et al. Methods Mol Med. 2005;113:245-56. doi: 10.1385/1-59259-916-8:245. Methods Mol Med. 2005. PMID: 15968108

8

Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma.

Martin SK, Dewar AL, Farrugia AN, Horvath N, Gronthos S, To LB, Zannettino AC. Martin SK, et al. Among authors: zannettino ac. Clin Cancer Res. 2006 Dec 1;12(23):6973-7. doi: 10.1158/1078-0432.CCR-06-0323. Clin Cancer Res. 2006. PMID: 17145816

9

Long-term imatinib therapy promotes bone formation in CML patients.

Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B, Zannettino AC. Fitter S, et al. Among authors: zannettino ac. Blood. 2008 Mar 1;111(5):2538-47. doi: 10.1182/blood-2007-07-104281. Epub 2007 Nov 27. Blood. 2008. PMID: 18042796 Free article.

10

Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss.

Diamond P, Labrinidis A, Martin SK, Farrugia AN, Gronthos S, To LB, Fujii N, O'Loughlin PD, Evdokiou A, Zannettino AC. Diamond P, et al. Among authors: zannettino ac. J Bone Miner Res. 2009 Jul;24(7):1150-61. doi: 10.1359/jbmr.090210. J Bone Miner Res. 2009. PMID: 19335218 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

217 results

Search Page